Evidence map›Paper›PMID 32302296›Full record

ArticlePLoS neglected tropical diseases2020

Click chemistry-facilitated comprehensive identification of proteins adducted by antimicrobial 5-nitroimidazoles for discovery of alternative drug targets against giardiasis.

Tineke Lauwaet, Yukiko Miyamoto, Sozaburo Ihara, Christine Le, Jarosław Kalisiak, Keith A Korthals, Majid Ghassemian, Diane K Smith, K Barry Sharpless, Valery V Fokin and 1 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Assessment of Drug Activities againstPathogens (Basel, Switzerland) · 2024
    Article
  3. Article
  4. Microbiology spectrum · 2022
    Article
  5. Characterization of Metronidazole-ResistantFrontiers in microbiology · 2022
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Tineke LauwaetDepartment of Pathology, University of California, San Diego, La Jolla, California, United States of America.
Yukiko MiyamotoDepartment of Medicine, University of California, San Diego, La Jolla, California, United States of America.
Sozaburo IharaDepartment of Medicine, University of California, San Diego, La Jolla, California, United States of America.ORCID 0000-0001-8495-2073
Christine LeDepartment of Medicine, University of California, San Diego, La Jolla, California, United States of America.
Jarosław KalisiakDepartment of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, United States of America.
Keith A KorthalsDepartment of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, United States of America.
Majid GhassemianDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California, United States of America.
Diane K SmithDepartment of Chemistry and Biochemistry, San Diego State University, San Diego, California, United States of America.
K Barry SharplessDepartment of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, United States of America.
Valery V FokinDepartment of Chemistry, Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, California, United States of America.
Lars EckmannDepartment of Medicine, University of California, San Diego, La Jolla, California, United States of America.ORCID 0000-0002-7987-8742
University of California San Diego · USScripps Research Institute · USSan Diego State University · USUniversity of Southern California · US

Funding

San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2019 to 2026
$10.8M
Next-generation 5-nitro heterocyclic antimicrobials against mucosal protistsR01AI114671 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ECKMANN, LARS · 2015 to 2019
$3.1M
Click chemistry for novel antimicrobials against periodontal pathogensRC1DE020607 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ECKMANN, LARS, FOKIN, VALERY V · 2009 to 2010
$962k
Acquisition of an Orbitrap Elite with ETDS10OD021724 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KOMIVES, ELIZABETH A. · 2016 to 2016
$600k
NIAID NIH HHS R01 AI114671NIDCR NIH HHS RC1 DE020607NIDDK NIH HHS P30 DK120515NIH HHS S10 OD021724
6 · The paper itself

Abstract

Giardiasis and other protozoan infections are major worldwide causes of morbidity and mortality, yet development of new antimicrobial agents with improved efficacy and ability to override increasingly common drug resistance remains a major challenge. Antimicrobial drug development typically proceeds by broad functional screens of large chemical libraries or hypothesis-driven exploration of single microbial targets, but both strategies have challenges that have limited the introduction of new antimicrobials. Here, we describe an alternative drug development strategy that identifies a sufficient but manageable number of promising targets, while reducing the risk of pursuing targets of unproven value. The strategy is based on defining and exploiting the incompletely understood adduction targets of 5-nitroimidazoles, which are proven antimicrobials against a wide range of anaerobic protozoan and bacterial pathogens. Comprehensive adductome analysis by modified click chemistry and multi-dimensional proteomics were applied to the model pathogen Giardia lamblia to identify dozens of adducted protein targets common to both 5'-nitroimidazole-sensitive and -resistant cells. The list was highly enriched for known targets in G. lamblia, including arginine deiminase, α-tubulin, carbamate kinase, and heat shock protein 90, demonstrating the utility of the approach. Importantly, over twenty potential novel drug targets were identified. Inhibitors of two representative new targets, NADP-specific glutamate dehydrogenase and peroxiredoxin, were found to have significant antigiardial activity. Furthermore, all the identified targets remained available in resistant cells, since giardicidal activity of the respective inhibitors was not impacted by resistance to 5'-nitroimidazoles. These results demonstrate that the combined use of click chemistry and proteomics has the potential to reveal alternative drug targets for overcoming antimicrobial drug resistance in protozoan parasites.

Indexed as

AnimalsAntiparasitic AgentsClick ChemistryDisease Models, AnimalDrug DiscoveryFemaleGiardia lambliaGiardiasisIndazolesIntestine, SmallMaleMice, Inbred C57BLParasite LoadProtein BindingProteomicsProtozoan Proteins5-nitroindazoleAntiparasitic AgentsIndazolesProtozoan Proteins

Identifiers

PMID32302296
PMCPMC7190177
OpenAlexW3017120209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.